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Prials and Tribulations of Non-Inferiority
he Ximelagatran Experience
anjay Kaul, MD,* George A. Diamond, MD, FACC,* William S. Weintraub, MD, FACC†
os Angeles, California; and Atlanta, Georgia
Ximelagatran is a novel oral direct thrombin inhibitor that offers a number of advantages over
the standard treatment, warfarin, in patients with atrial fibrillation. Two large clinical trials,
one open-label (Stroke Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation
[SPORTIF] III), one double-blind (SPORTIF V), have compared the efficacy and safety of
fixed-dose ximelagatran without anticoagulation monitoring with dose-adjusted warfarin
using a non-inferiority design. On the basis of the results, the investigators concluded that
ximelagatran was just as effective as warfarin in preventing stroke or systemic embolism (the
primary end point), because the pre-specified non-inferiority criterion was met. Reanalysis of
the data with rather conservative interpretive criteria, however, revealed a number of
deficiencies: 1) an unreasonably generous margin that was potentially biased toward
non-inferiority, given the low baseline event rate of warfarin; 2) the inappropriateness of the
analytical method used to estimate the non-inferiority margin; 3) a lack of confidence that
ximelagatran retains at least 50% of warfarin’s effect (a prerequisite to the establishment of
non-inferiority); 4) significant heterogeneity in the magnitude of efficacy observed in the two
trials; and 5) safety concerns regarding increased liver toxicity with ximelagatran without a
significant offsetting advantage in major bleeding. This imbalance in the benefit-risk profile
materially undermines the investigators’ claim of non-inferiority of ximelagatran and led the
Food and Drug Administration to reject the sponsor’s application for ximelagatran. Despite
published conclusions to the contrary, we conclude that ximelagatran has not been shown to
be non-inferior to warfarin. Such determinations of non-inferiority are highly dependent on
the underlying assumptions, and graphical sensitivity analyses make this dependence
explicit. (J Am Coll Cardiol 2005;46:1986–95) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.062Cardiology Foundation
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aonvalvular atrial fibrillation (AF) is associated with an
ncreased risk of ischemic stroke and systemic embolization
1). Anticoagulation therapy with warfarin reduces this risk
y approximately two-thirds (1,2). Aspirin is generally less
ffective than warfarin, but evidence suggests that it is superior
o placebo, especially in low-risk patients (1). Despite the
ompelling evidence that anticoagulation with warfarin re-
uces the risk of stroke in most patients with AF, this
herapy continues to be underused, with fewer than one-half
f eligible patients taking it (3).
Alternative approaches to anticoagulation have resulted
n the development of an oral direct thrombin inhibitor,
imelagatran (4–6), which offers several practical advan-
ages over warfarin. It has a stable and predictable pharma-
okinetic profile that is independent of body weight and
ther patient variables, rapid onset and offset of action, and
inimal interaction with diet and drugs, thereby eliminating
he need for anticoagulation monitoring and dose adjustment.
he safety and efficacy of ximelagatran in patients with AF at
isk for ischemic stroke has been evaluated in two phase-III
tudies within the Stroke Prevention Using Oral Thrombin
nhibitor in Atrial Fibrillation (SPORTIF) program (4–6).
From the *Division of Cardiology, Cedars-Sinai Medical Center, and the David
effen School of Medicine, University of California, Los Angeles, California; and the
Emory Center for Outcomes Research, Emory University, Atlanta, Georgia.n
Manuscript received May 21, 2005; revised manuscript received July 6, 2005,
ccepted July 11, 2005.The SPORTIF III study was a randomized, open-label
arallel group trial that sought to determine if ximelagatran,
dministered in a 36-mg twice-daily fixed dose, was non-
nferior to the current efficacy standard of warfarin (dose-
djusted to an international normalized ratio of two to
hree) for prevention of strokes and systemic embolic events
n 3,407 patients with nonvalvular AF and, at least, one
troke risk factor (4). The SPORTIF V trial was similar, but
ith double-blind treatment allocation involving 3,922 pa-
ients (6). The primary efficacy and secondary safety results are
ummarized in Table 1.
On the basis of these results, the SPORTIF investigators
oncluded that “ximelagatran treatment is at least as effec-
ive as well-controlled warfarin treatment for prevention of
troke and systemic embolism [and] might have a more
avorable benefit/risk profile than warfarin for patients with
trial fibrillation” (4–6). As a result of these findings, the
orporate sponsor submitted a new drug application to the
ood and Drug Administration (FDA). Nevertheless, on
ctober 8, 2004, the FDA rejected the application on the
ecommendation of its Cardiovascular and Renal Drugs
dvisory Committee, owing to concerns over safety and, to
lesser degree, the method of measuring efficacy (7). An
nderstanding of this decision requires a deeper apprecia-
ion of the methods and assumptions underlying the design
nd analysis of the SPORTIF trials, in particular, and of
on-inferiority trials in general.
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December 6, 2005:1986–95 Non-Inferiority Analysis of the SPORTIF TrialsThe non-inferiority design employed in the SPORTIF
rial, unlike a placebo-controlled design, compares the new
xperimental treatment with the current standard treatment
“active control”) rather than placebo. This design is justi-
ed whenever treatment with placebo is considered “uneth-
cal,” as in the SPORTIF trial (4–6). The critical issues
nvolved in non-inferiority trials are highlighted in Table 2.
here are two basic approaches to non-inferiority analysis
8–15). The first approach seeks to determine if the new
reatment is inferior to the active control treatment by no
ore than some pre-defined margin (“marginal analysis”).
he second approach seeks to determine if the new treat-
ent preserves some pre-defined fraction of the standard
reatment’s effect (“fractional analysis”). Both of these ap-
roaches introduce a number of statistical assumptions, not
lways specified or justified. Our goal is to describe the
ritical assumptions underlying the design and analysis of
he SPORTIF trial and to explore the robustness of its
onclusions with respect to these assumptions.
ON-INFERIORITY TRIAL DESIGN
arginal analysis of non-inferiority. One of the most
rucial steps in the non-inferiority trial design is the
pecification of a non-inferiority margin which quantifies
able 1. Primary Results of Stroke Prevention Using Oral Throm
Ximelagatran
(%/yr)
Warfa
(%/
PORTIF III (n  3,407)
Stroke or systemic embolism (ITT) 1.6 2.
Stroke or systemic embolism (OT) 1.3 2.
Major bleeding (OT) 1.3 1.
ALT 3  ULN (OT) 6.3 0.
Withdrawal rate due to adverse events 10.9 5.
PORTIF V (n  3,922)
Stroke or systemic embolism (ITT) 1.6 1.
Stroke or systemic embolism (OT) 1.6 1.
Major bleeding (OT) 2.4 3.
ALT 3  ULN (OT) 6.0 0.
Withdrawal rate due to adverse events 18.1 15.
PORTIF III  V (n  7,329)
Stroke or systemic embolism (ITT) 1.6 1.
Major bleeding (OT) 1.9 2.
ALT 3  ULN (OT) 6.1 0.
Withdrawal rate due to adverse events 14.7 10.
Abbreviations and Acronyms
AF  atrial fibrillation
CI  confidence interval
FDA  Food and Drug Administration
SPORTIF  Stroke Prevention Using Oral Thrombin
Inhibitor in Atrial Fibrillationwo-sided p values are shown.
ALT  alanine aminotransferase; ITT  intention-to-treat; OT  on treatment; ULNhe worst case loss in efficacy that is clinically acceptable,
onsidering the potential safety, convenience, or cost advan-
ages of the new treatment. No universally accepted “gold
tandard” criterion exists for estimation of this margin
8–15). The International Conference on Harmonization
uidance (16) advises that the determination of the margin
hould be: 1) specified a priori, 2) on the basis of both
linical judgment and statistical reasoning, and 3) suitably
onservative, reflecting the uncertainty in evidence.
A clinically accepted norm for non-inferiority margin is a
roportional difference of 15% to 20% or less, smaller than
he typical 20% to 25% “minimally clinically important
ifference” criterion employed in superiority trials; however,
hat constitutes a clinically acceptable difference is ulti-
ately a matter of judgment and might vary widely for each
atient, physician, investigator, regulator or payor, and the
linical circumstance. For example, any difference in hard
utcomes like mortality or irreversible morbidity (myocar-
ial infarctions or disabling stroke) might be argued to be
linically meaningful, thereby warranting the choice of
arrow conservative margins. In contrast, a larger reduction
n efficacy and, therefore, a more liberal margin might be
olerable if the outcome is less robust, as with any reversible
orbidity (recurrent ischemia or transient ischemic attack),
nd if the new treatment offers significant improvements in
dministration, adverse effects, and cost.
Despite the emphasis on clinical judgment, the deciding
actor for determination of the margin is often statistical,
iven the subjective and somewhat arbitrary nature of the
ormer. From a statistical perspective, the margin should be,
t the very least, no larger than the worst limit of 95%
onfidence interval (CI) of standard treatment effect relative
o placebo (8,13,14), but it could be smaller so as to have
ssurance that the new treatment has greater than minimal
Inhibitor in Atrial Fibrillation (SPORTIF) III and V Studies
Absolute Difference
(95% CI)
Risk Ratio
(95% CI) p Value
0.66 (1.44 to 0.12) 0.71 (0.48 to 1.07) 0.1
0.94 (1.69 to 0.19) 0.57 (0.36 to 0.90) 0.02
0.50 (1.22 to 0.22) 0.71 (0.44 to 1.13) 0.23
5.5 (4.2 to 6.7) 7.64 (4.39 to 13.28) 0.0001
4.98 (3.13 to 6.84) 1.85 (1.46 to 2.34) 0.0001
0.45 (0.13 to 1.03) 1.38 (0.91 to 2.10) 0.13
0.55 (0.06 to 1.16) 1.47 (0.91 to 2.36) 0.09
0.70 (1.50 to 0.10) 0.75 (0.54 to 1.03) 0.16
5.20 (4.30 to 6.10) 7.38 (4.40 to 12.40) 0.0001
2.77 (0.44 to 5.10) 1.18 (1.03 to 1.36) 0.02
0.03 (0.44 to 0.50) 0.98 (0.73 to 1.30) 0.94
0.60 (1.27 to 0.07) 0.76 (0.56 to 1.03) 0.07
5.30 (4.58 to 6.02) 7.6 (5.47 to 10.62) 0.001
3.80 (2.27 to 5.32) 1.35 (1.19 to 1.52) 0.0001bin
rin
yr)
3
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9 upper limit of normal.
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Non-Inferiority Analysis of the SPORTIF Trials December 6, 2005:1986–95fficacy (10). One proposal for selecting the margin is to
ake one-half of the magnitude of the worst limit of this
I—the so-called “50% rule” or “95-95 method” recom-
ended by the FDA (13,14). This conservative margin,
owever, often results in a high “false-negative” rate (type II
rror; i.e., low power to demonstrate non-inferiority). In
eneral, the objective should be to limit “false-positive”
type I) errors by avoiding too liberal a margin and “false-
egative” (type II) errors by avoiding too conservative a
argin with respect to a claim of efficacy. The margin is
enerally set in terms of an absolute or relative difference,
he latter being favored over the former given its greater
rial-to-trial stability (10). The active control effect is best
etermined from a random effects meta-analysis to account
or trial-to-trial variability (8,10,13,14).
stimation of the non-inferioritymargin for SPORTIF. Fig-
re 1 summarizes the estimation of the non-inferiority
argin. The warfarin effect has been assessed in six placebo-
ontrolled studies (17–22), five of which enrolled patients
ithout and one (European Atrial Fibrillation Trial
able 2. Critical Issues in the Design Conduct and Analysis of N
. Trial design
1. Ethical imperative
New therapy should offer advantages in cost, safety, convenience, a
2. Estimation of active control effect
Based on more than one placebo-controlled trial and estimated rel
3. Estimation of non-inferiority margin
a. Specified a priori on the basis of “clinical judgment” and “statist
i. Clinical judgment: i. Should be smaller than the proportion
employed in superiority trials, preferab
ii. Should be predicated on clinical outco
ii. Statistical reasoning: i. Should not be greater than the 95% lo
one-half of 90 or 95% lower limit of a
ii. Should minimize “false-positive” error
or too conservative a marginal thresho
b. Fixed estimate of relative risk difference (risk, odds, or hazard ra
. Trial conduct
Proper trial conduct to maintain assay sensitivity (discriminate effecti
a. Enroll appropriate patients likely to respond to treatment
b. Maximize compliance and minimize drop-out rate and non-protoc
c. Avoid misclassification of outcomes
. Statistical analysis
1. Marginal analysis
a. Indirect confidence interval (CI) comparison
one-sided 97.5% (or two-sided 95%) CI for difference
b. Hypothesis testing
Null hypothesis (H0): risk difference margin
Alternative hypothesis (HA): risk difference margin
2. Fractional analysis
a. Superiority over placebo (“putative placebo approach”)
b. Fraction preservation of active control
3. Bayesian analysis
a. Marginal analysis: probability of non-inferiority
b. Fractional analysis
Superiority over putative placebo
Fraction preservation of active control
4. Intention-to-treat and on-treatment analysis
5. Sensitivity analyses for margin and fraction preservation or bothEAFT]) with recent transient ischemic attack or stroke. pecause the EAFT study enrolled a higher risk population
han did the SPORTIF trial, one can justify not including
t in the estimation of the summary effect of warfarin. The
PORTIF investigators assumed a baseline warfarin event
ate of 3.1%/year and a non-inferiority margin of 2% in
erms of absolute difference, representing their estimate of
he maximal difference considered to be clinically acceptable
4,6). This margin, however, is approximately equivalent to
he 95% lower limit of the absolute risk difference derived
rom the five pooled trials. Taking 50% of this limit, as
uggested by the “50% rule,” results in a margin of 1%,
ne-half of that of the margin used by the SPORTIF trial.
ith meta-analysis, the margin is estimated to be even
maller—0.85% for a fixed-effects model and 0.68% for a
andom-effects models. The corresponding margins in
erms of risk ratio vary from 1.22 for an absolute margin of
.68% to 1.65 for an absolute margin of 2% at an expected
arfarin rate of 3.1% (Fig. 1). Thus, the non-inferiority risk
atio margin of 1.65 in the SPORTIF trial was unreasonably
enerous, exceeding those typically encountered in contem-
nferiority Trials
on, over the current standard treatment (active control)
using a random-effects meta-analytical model
asoning” and should be suitably conservative
–25% “minimum clinically important difference” (MCID) criterion
e-half of the MCID
d benefit-risk and benefit-cost profile
imit of active control effect, but could be smaller; FDA recommends
control effect as a conservative estimate of margin (“50% rule”)
I error) and “false-negative” error (type II error) by avoiding too liberal
pectively
referred over absolute risk difference
m ineffective treatments)
ncomitant medications
on-inferiority criterion
pper bound of CI margin
-sided p  0.025 to reject H0
5% CI of relative risk difference 1.0
t least 0.5 fraction (95% CI 0.5)
robability of difference margin 0.975
robability of 0 fraction preservation of active control effect 0.95
robability of 0.5 fraction preservation of active control effect 0.95
oncordant results strengthen non-inferiority
ower margin and higher fraction increase strength of evidenceon-I
nd so
iably
ical re
al 20%
ly on
me an
wer l
ctive
(type
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December 6, 2005:1986–95 Non-Inferiority Analysis of the SPORTIF Trialshe Randomized Evaluation in PCI Linking Angiomax to
educed Clinical Events (REPLACE II) (1.18), Valsartan
n Acute Myocardial Infarction (VALIANT) (1.13), Prav-
statin or Atorvastatin Evaluation and Infection Therapy
PROVE-IT) (1.17), Superior Yield of the New strategy of
noxaparin, Revascularization, and GlYcoprotein IIb/IIIa
nhibitors (SYNERGY) (1.10), and Aggrastat to Zocor
A-to-Z) (1.11). The risk ratio margin would have been
ven higher (nearly 2.0) had the investigators chosen an
ppropriate warfarin rate—their choice for the warfarin rate
igure 1. Estimation of the non-inferiority margin for Stroke Prevention U
ata for the six historical studies of warfarin versus placebo are shown abo
re shown below the dashed line for all six trials (n  6) and five primar
5). Summary effects were calculated with pooled analysis derived by addin
MA), and DerSimonian-Laird method for random-effect MA. The ma
ifference (ARD) derived from a random-effects MA (e.g., 50% of 1.36%
ssumed warfarin event rate of 3.1% (e.g., ARD of 0.68  RR 1.22 [
nticoagulation; BAATAF  Boston Area Anticoagulation Trial for Atr
ouble-blind; OL  open-label; SP  secondary prevention; SPAF I 
on-Rheumatic Atrial Fibrillation.
igure 2. Marginal analysis of non-inferiority for Stroke Prevention Using O
s point estimates and 95% confidence interval (CI) for absolute (left)
n-treatment (OT) populations. The vertical dashed lines represent non-
wo-sided 95% CI (equivalent to one-sided 97.5% CI) is less than the margin. Su
or 1.0 risk ratio).3.1%) exceeded the rate supported by historical pooled data
1.9%) by more than 50%.
arginal analysis of the SPORTIF trial. The primary
on-inferiority analyses reported for the SPORTIF III and
PORTIF V trials are shown in Figure 2. Unlike superiority
rials, in which intention-to-treat (ITT) is preferred to
n-treatment (OT) analysis, the ITT analysis is biased
oward non-inferiority. Hence, both analyses should be
erformed for a non-inferiority trial, similar results support-
ng the robustness of the conclusion (8,13,14). Non-
ral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) trial. Individual
e dashed line. Summary effects and estimation of non-inferiority margin
ention (PP) (minus European Atrial Fibrillation Trial [EAFT]) trials (n
he events together, Mantel Haenszel method for fixed-effect meta-analysis
s typically estimated as 50% of the 95% lower limit of the absolute risk
.68%). The corresponding risk ratio (RR) margins are on the basis of an
0.68)/3.1  3.78/3.1]). AFASAK  Atrial Fibrillation, Aspirin and
brillation; CAFA  Canadian Atrial Fibrillation Anticoagulation; DB 
ke Prevention in Atrial Fibrillation I; SPINAF  Stroke Prevention in
hrombin Inhibitor in Atrial Fibrillation (SPORTIF) trial. Data are shown
relative (right) difference in outcome for intention-to-treat (ITT) and
ority margins. Non-inferiority is established when the upper bound of thesing O
ve th
y prev
g all t
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 0
(3.1 
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Non-Inferiority Analysis of the SPORTIF Trials December 6, 2005:1986–95nferiority is established for all margins in the SPORTIF III
rial for both ITT and OT analyses. Superiority of ximel-
gatran over warfarin is established in the SPORTIF III
rial for OT analysis. In contrast, non-inferiority is estab-
ished only for a margin of 2% with respect to absolute
ifference and is not established for any margin with respect
o risk ratio in the SPORTIF V trial. According to this
nalysis, an inference of non-inferiority is highly sensitive to
ne’s choice of the non-inferiority margin—the higher the
argin, the easier it is to establish non-inferiority. A
ensitivity analysis over a continuous range of values is
hown in Figure 3. Non-inferiority is supported in the
PORTIF V trial only for an absolute risk difference
1.04% and a risk ratio 1.87. Such margins are arguably
oo liberal to be considered clinically relevant. In contrast,
he marginal threshold for non-inferiority for the SPOR-
IF III trial is suitably conservative—an absolute risk
ifference of 0.17% or a risk ratio of 1.05.
ractional analysis of non-inferiority. Unlike placebo-
ontrolled superiority trials, non-inferiority trials do not
rovide a direct way to distinguish effective from ineffective
herapies (i.e., the two therapies could be equally effective
r equally ineffective). Many non-inferiority analyses are
onducted on the tacit assumption that the new and
tandard treatments would have demonstrated effective-
ess when compared directly with placebo had such a
omparison been made, fulfilling the so-called require-
ent of “assay sensitivity” (8,10 –15). One can perform
uch a comparison, albeit indirectly, via the “putative
lacebo” approach. The effect of the new treatment versus
putative” placebo is imputed from the observed effects in
he current trial and the historical placebo-controlled
rials of the standard treatment, as illustrated in Figure 4
igure 3. Sensitivity analysis of marginal non-inferiority for Stroke Prevent
re shown for absolute difference (left) and risk ratio (right). The one-s
PORTIF V (2%, 1%, and 0.68%) were 0.001, 0.034, and 0.225, respec
he dashed line) (9).11–15). The putative placebo approach makes a critical nssumption of “constancy,” to the effect that the standard
reatment performs as it did in previous placebo-
ontrolled trials. In practice, this assumption is not
ecessarily plausible because of differences in patient
haracteristics, concomitant medications, intensity of
reatment, and other key design features (12–15). One
ay to “discount” for this limitation is by estimating the
raction of the standard treatment effect retained by the
ew treatment. This is determined as a ratio of the
mputed effect of the new treatment versus putative
lacebo relative to the effect of the standard treatment
ersus placebo along with its estimated variance and CI
12–15). Non-inferiority is inferred if the CI of this
raction exceeds a pre-specified minimum threshold (ar-
itrarily, 0.5) that is considered to be “clinically impor-
ant” (i.e., the 95% lower limit should exceed 0.5 fraction)
12–15). Thus, for a new treatment to be declared
ffective, it must not only be superior to the putative
lacebo but it must also preserve a pre-specified fraction
f the standard treatment’s effect.
ractional analysis of the SPORTIF trial. Comparison
f ximelagatran versus putative placebo is shown in Figure
. Superiority is established for all three analyses—
imelagatran exhibited a 73% relative risk reduction (95%
I, 56% to 85%) relative to placebo in the SPORTIF III
rial, 48% relative risk reduction (95% CI, 14% to 69%) in
he SPORTIF V trial, and a 63% relative risk reduction
95% CI, 45% to 76%) in the SPORTIF IIIV trial.
on-inferiority is established in the SPORTIF III trial and in
he combined SPORTIF IIIV trial analyses but not in the
PORTIF V trial alone with the liberal “lower bound” crite-
ion. With the more conservative “upper bound” criterion (15),
sing Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) trial. Data
values for non-inferiority for the three margins shown in Figure 2 for
. Non-inferiority is supported if the one-sided p  0.025 (represented byion U
ided p
tivelyon-inferiority is established only for the SPORTIF III trial.
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December 6, 2005:1986–95 Non-Inferiority Analysis of the SPORTIF TrialsAgain, because non-inferiority depends on one’s arbitrary
hoice of the threshold fraction—the lower the fraction, the
asier it is to establish non-inferiority—a sensitivity analysis
s best performed to define the robustness of this choice. On
igure 4. Putative placebo analysis for Stroke Prevention Using Oral Thr
f ximelagatran versus “putative” placebo from data derived from SPORT
utative placebo approach is illustrated where the estimate of risk ratio of
he risk ratio of ximelagatran relative to warfarin (observed risk ratio), from
isk ratio). Historical risk ratio is obtained from a random-effect meta-analy
re 0.27 (0.16 to 0.44) for SPORTIF III, 0.52 (0.31 to 0.86) for SPORT
lacebo is established if the derived risk ratio is 1.0. Non-inferiority is e
he fractional threshold estimated as a fraction (arbitrarily 50%) of the “his
s the square root of the “historical risk ratio” and is equivalent to 0.61 (0
ractional threshold for non-inferiority. In contrast, the upper bound (UB
igure 5. Sensitivity analysis of fractional non-inferiority for Stroke Pre-
ention Using Oral Thrombin Inhibitor in Atrial Fibrillation V trial.
on-inferiority, assessed at 0.5 fraction retention of the warfarin treat-
ent, is supported if one-sided p  0.025 (represented by the lower
ashed line). Superiority to placebo and warfarin is assessed at 0 and 1.0
raction, respectively. The point estimate and the lower and upper limit of
ne-sided 97.5% confidence interval (CI) (equivalent to two-sided 95% CI)
f the fraction of warfarin’s effect preserved by ximelagatran are shown as
ractional values corresponding to the 50th (middle dashed line), 2.5thi
lower dashed line), and 97.5th (upper dashed line) percentile of
istribution, respectively.he basis of this analysis shown in Figure 5 for the
PORTIF V trial, non-inferiority is not supported at the
onventional fractional threshold of 0.5 but only for fractions
0.2. Although superiority of ximelagatran to placebo (as-
essed at 0 fraction) is established, there is some suggestion that
arfarin is actually superior to ximelagatran (assessed at 1.0
raction; one-sided p  0.06).
The fraction of the warfarin effect retained by ximelagat-
an can also be estimated from Figure 5 and is equivalent to
.67 (0.19 to 1.10), corresponding to the 50th (p  0.5),
.5th (p  0.025) and 97.5th (p  0.975) percentile of the
istribution, respectively. With a different approach, the
asselblad and Kong method (12), the fraction retained is
stimated to be 0.67 (0.37 to 0.97). Because the CI of both
f these estimates contains the pre-specified fractional
hreshold of 0.5, the data do not support a claim of
on-inferiority. Thus, in contrast to the “official” conclusion
egarding the SPORTIF V trial, these fractional analyses
re inconsistent with a claim of non-inferiority relative to
arfarin.
ayesian analysis of non-inferiority. The Bayesian ap-
roach to hypothesis testing can be employed for determi-
ation of non-inferiority. Briefly, normal posterior distribu-
ions are derived with the log mean risk ratio () and its
tandard deviation () according to Bayes’ theorem, which
tates that the probability for the hypothesis (non-
nferiority), given the evidence (the “posterior”), is propor-
ional to the probability for the evidence, given the hypothesis
the “likelihood”) times the probability for the hypothesis
Inhibitor in Atrial Fibrillation (SPORTIF) trials. Imputed comparisons
I, SPORTIF V, and combined SPORTIF IIIV trials are shown. The
lagatran relative to placebo (derived risk ratio) is obtained by multiplying
current trial, by the historical warfarin versus placebo risk ratio (historical
five primary prevention trials and is 0.37 (0.28 to 0.50). Derived risk ratios
, and 0.37 (0.24 to 0.55) for SPORTIF IIIV. Superiority over putative
shed if the worst (upper) limit of the “derived risk ratio” does not exceed
l risk ratio.” In SPORTIF trials, this estimate is obtained mathematically
o 0.71). The lower bound (LB) of this interval (0.71) represents a liberal
his interval (0.53) constitutes a conservative fractional threshold (15).ombin
IF II
xime
the
sis of
IF V
stabli
torica
.53 t
) of tndependent of the evidence (the “prior”) (23–25).
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Non-Inferiority Analysis of the SPORTIF Trials December 6, 2005:1986–95Essential to Bayesian analysis is the choice of prior and
he weight assigned to that prior (23,25). Briefly, priors
ange from the uninformative, which impart no information
expressed mathematically as   0,  1), to the
keptical, which express cautiously reasonable skepticism
bout efficacy of the new treatment, to the informative,
hich impart substantial information from previous clinical
rials. The uninformative prior has the least influence on the
nalysis; inferences on the basis of it are equivalent to the
onventional frequentist results. The informative prior is
specially helpful if the previous clinical trial from which it
s derived closely resembles the current non-inferiority trial.
ny differences in patient characteristics, study protocols, or
utcome assessment between the current and historical trial
an be accounted for by discounting the latter relative to the
ormer by varying the proportion or weight assigned to the
rior information (23). The influence of these choices on
he resultant probability of non-inferiority can be assessed
hrough sensitivity analysis. An analysis that is insensitive to
he choice of prior indicates a greater degree of stability in
he resultant inferences.
The advantages of the Bayesian approach, and its applica-
ions to non-inferiority trials, are reviewed in greater detail
lsewhere (23–25). In general, Bayesian analysis replaces a
ategorical (yes/no) non-inferiority judgment with a contin-
ous probability statement relative to the non-inferiority
ypothesis. Accordingly, the probability of non-inferiority
elative to any assumed marginal or fractional threshold can
e computed, and non-inferiority is thereby inferred at a
osterior probability of0.975 (corresponding to a conven-
ional one-sided p  0.025).
ayesian analysis of the SPORTIF trial. Figure 6 shows
igure 6. Bayesian analysis of Stroke Prevention Using Oral Thrombin I
thick line) distributions derived from integrating evidence or likelihood
ccording to Bayes’ theorem. The margin of non-inferiority (M) is indica
equivalent to a risk ratio of 1.65). Three priors are used: 1) uninformativ
og-RR mean ()  0, standard deviation ()  10; likelihood and posteri
i.e., 50% of the distribution is contained within the non-inferiority marg
nformation derived from SPORTIF III trial (log-RR   0.338,   0.
nder the curve. The probabilities of falling below (M), within ( M
robability of non-inferiority is computed as the sum of probability of M
rior [plot # 1] is 0.068 [M]  0.736 [ M]  0.804). Non-inferiority
 0.025).osterior probability distributions for the SPORTIF V trial Tith three different priors, as detailed in the figure legend.
he probability of non-inferiority with the pre-defined risk
atio margin of 1.65 (equivalent to a log risk ratio of 0.5) is
.804, 0.913, and 0.999 with an uninformative, skeptical,
nd informative prior, respectively. Thus, non-inferiority is
stablished (posterior probability 0.975) only when prior
nformation from the SPORTIF III trial is used. The
robability of non-inferiority is directly proportional to the
agnitude of the margin and the weight of prior informa-
ion and exceeds the threshold of 0.975 for all weights (0 to
) with the investigators’ absolute difference margin of 2%
1.65 risk ratio) but only for weights0.4 for a conservative
bsolute difference margin of 0.68% (1.22 risk ratio; i.e.,
0% or higher portion of data from the SPORTIF III trial
s required to establish non-inferiority at a conservative
arginal threshold in the SPORTIF V trial). Thus, the
ower the prior weight, the lesser the dependence on prior
tudies and the stronger the evidence of non-inferiority.
ISCUSSION
wo large non-inferiority trials have concluded that “ximel-
gatran is at least as effective as warfarin” in preventing
troke and systemic embolism in patients with nonvalvular
F (4–6); however, our re-assessment reveals several lim-
tations in the design and analysis of the data that refute the
nvestigators’ interpretation and point to a contrary conclu-
ion. On the basis of the pivotal double-blind SPORTIF V
rial, there is, in fact, very little evidence that ximelagatran is
on-inferior to warfarin, unless one uses a liberal non-
nferiority margin that is not supported by historical studies.
or in Atrial Fibrillation (SPORTIF) V trial. Tri-plots showing posterior
line) from SPORTIF V trial and three different priors (dashed line),
the two vertical dotted lines and is equivalent to a log risk ratio of 0.5
r, intended to add as little as possible to the data (formally expressed as
tributions are superimposed, hence only one plot); 2) moderately skeptical
g-RR   0.250,   0.374]); and 3) informative, on the basis of prior
Posterior probability of any effect size can be calculated by computing area
bove M (M) are shown on the top right-hand corner of each plot.
 M (e.g., the posterior probability of non-inferiority with uninformative
ferred at a posterior probability of 0.975 (corresponding to a one-sidednhibit
(thin
ted by
e prio
or dis
in [lo
241).
), or a
plus
is inhe best case scenario indicates a negligible benefit of
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December 6, 2005:1986–95 Non-Inferiority Analysis of the SPORTIF Trialsimelagatran over warfarin—a 0.13% absolute or 9% relative
isk reduction and 110% retention of warfarin’s effect. In
ontrast, the worst case scenario reflects a 1% absolute loss
f benefit or a 2-fold relative increase in risk and 20%
reservation of the warfarin effect.
This loss in efficacy would have been tolerable if ximel-
gatran had been shown to have other noteworthy benefits
less toxic, less costly, easier to administer) that outweigh
he seeming loss of efficacy; however, this is not the case,
wing to major safety concerns over increased liver toxicity
nd increased withdrawal rate associated with ximelagatran
n comparison with warfarin. Even though the incidence of
ajor bleeding is numerically greater with warfarin, the
ifference is not statistically significant. Thus, the potential
harmacologic advantages and ease of administration of
imelagatran without the need for monitoring or dose
itration are offset by reduced efficacy, increased safety
oncerns, and potentially increased cost. This imbalance in
he benefit-risk and potentially benefit-cost profile chal-
enge the investigators’ claim of non-inferiority of ximel-
gatran and led the FDA against recommending ximelagat-
an for approval.
ritical issues in the design and analysis of non-
nferiority trials. The results of the SPORTIF trials high-
ight several fundamental issues in the design and analysis of
on-inferiority trials, as summarized in Table 2. The choice
f the non-inferiority margin is a key step. Several points are
orthy of consideration with respect to the non-inferiority
argin in the SPORTIF trials.
First, one might argue that the 2% margin was unreason-
bly generous and potentially biased toward non-inferiority,
iven the low baseline event rate in this study. If the
nvestigators had chosen a smaller, more conservative mar-
in, they would not have drawn the conclusion that ximel-
gatran was non-inferior to warfarin.
Second, there is uncertainty about the magnitude of the
arfarin effect because of the variability between the five
istorical trials in terms of the design and the observed results.
nly two of the five trials were double-blind (Fig. 1), and four
ere stopped prematurely because of significant benefits ob-
erved on interim analysis (18–21). Given this variability, a
andom-effects meta-analytical model, which allows for differ-
nces in treatment effects between studies, would have pro-
ided a reliable estimate of the warfarin effect compared
ith the fixed-effects model or the pooled analysis.
Third, the decision to employ absolute or relative differ-
nce as the basis for judgments regarding non-inferiority is
rbitrary. In general, relative differences provide more con-
ervative thresholds than absolute differences when event
ates are changing and/or unpredictable (as in the SPOR-
IF trial, where the observed event rates were lower than
he assumed rate) owing to differences in patient popula-
ions or new modalities of treatment (8,11). Accordingly, an
nalysis of the SPORTIF V trial on the basis of risk ratio is
nconsistent with the “official” analysis on the basis of
bsolute difference, the observed upper bound of 2.1 being (reater than the non-inferiority risk ratio margin of 1.65.
on-inferiority becomes even more difficult to establish
ith more conservative relative margins. In such cases, a
udgment of non-inferiority would be more confident if
nalyses on the basis of absolute and relative difference were
oncordant.
Finally, the impact of active control event rate and
on-inferiority margin on sample size is quite substantial.
or a relative risk margin of 1.65, the total sample size
equired to ensure 90% power increases from 3,156 in the
PORTIF V trial at an expected warfarin event rate of
.1%/year to 4.875 at the pooled historical warfarin rate of
.9% per year and to 8,190 at the actually observed warfarin
ate of 1.2%/year. More conservative margins would also
equire greater sample sizes at any given warfarin rate with
he sample size increasing as the reciprocal of the square of
he margin (13,14). Thus, both SPORTIF trials were
rguably underpowered (resulting in a high “false-negative”
ype II error) to determine the relative efficacy of ximelagat-
an versus warfarin, given lower than expected warfarin
vent rates.
Although the size of the margin is determined by trial
ogistics (the larger the margin, the smaller the trial), a
otentially serious consequence of choosing liberal margins
s “biocreep,” a well recognized phenomenon that can occur
hen a slightly inferior treatment becomes the active
ontrol for future non-inferiority trials and so on until the
ctive control becomes no better than a placebo (13,14).
deally, stringent margins on the basis of the best compar-
tor should be used to enhance the strength and credibility
f non-inferiority trials; however, such stringent margins
ften result in large sample sizes that render the trials
mpractical. Reconciling these two important considerations
f feasibility and stringency poses a substantial challenge. In
his article, we have shown how a sensitivity analysis across
range of margins, from liberal to clinically relevant to
onservative (reflecting the core philosophies of the sponsor,
ractitioner, and regulator, respectively), might provide
seful insights.
Another key aspect of the non-inferiority inference is its
eliance on two critical assumptions: assay sensitivity defined
s the ability to detect differences between treatments if such
ifferences exist; and constancy, which assumes that the
istorical difference between the active control and placebo
ill be constant in the setting of the current active control
rial if a placebo control had been used (8,10–15). The
alidity of these two key assumptions, however, cannot be
erified directly. Assay sensitivity is affected by poor trial
esign and conduct that does not ensure maximal compli-
nce, minimization of protocol deviations, and outcome
isclassifications (Table 2). The constancy assumption
annot be plausibly demonstrated because of differences
ith respect to patient characteristics, concomitant medica-
ions, intensity of treatment, and other key design features
12–15). Given this limitation, it seems reasonable to raise
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Non-Inferiority Analysis of the SPORTIF Trials December 6, 2005:1986–95he standard of evidence required for the establishment of
on-inferiority.
Both marginal and fractional analyses are considered to
e forms of “discounting” to raise the standard of evidence
15). The “50% rule” endorsed by the FDA represents a
orm of “double discounting,” in which preservation of a
raction of the active control effect is applied to the
on-inferiority margin to make it “suitably conservative”
16). The fractional approach addresses the issue of con-
tancy by discounting the historical data when the event
ates are dissimilar in the current and historical trials (15). In
he SPORTIF V trial, the observed warfarin rate of 1.2% was
early 50% lower than the historical rate of 1.9%. Thus, a
roper discounting via fractional analysis would have mini-
ized the type I error and led the SPORTIF investigators
way from an erroneous conclusion of non-inferiority.
mplications. One’s choice of the statistical approach to
nference has important implications in the interpretation of
on-inferiority trials. In this context, the Bayesian approach
ffers a number of advantages over the conventional fre-
uentist approach (23–25). Chief among them is the inte-
ration of prior information with the empirical data to
pgrade the evidence. Any degree of heterogeneity between
he current and prior trial can be corrected by varying the
roportion or weight assigned to the prior information (23).
or example, there is substantial heterogeneity in the
rimary outcome between the SPORTIF III and SPOR-
IF V trials (p 0.03) (5) that might be related to bias due
o lack of blinding in the SPORTIF III trial or to other
onfounding factors such as significantly greater degree of
oncomitant aspirin use in the ximelagatran group in the
PORTIF III trial (4,5). Bayesian analysis supports the
ppropriateness of lowering the marginal threshold for non-
nferiority via incorporation of prior information, thereby
trengthening the evidence in favor of non-inferiority. It is
xactly in this way—by taking optimum advantage of the
vailable prior information—that the Bayesian approach
ffers a major advantage over the frequentist approach.
deally, robust conclusions regarding non-inferiority should
e on the basis of concordant analyses with both
pproaches.
In conclusion, a variety of subtle assumptions challenge
he design, analysis, and interpretation of non-inferiority
rials. Among these are the arbitrary thresholds employed
or the characterization of “non-inferiority” and the use of
istorical controls to derive the effect of the new treatment
elative to a hypothetical putative placebo. In the extreme,
his trial design might result in a “regression toward medioc-
ity” whereby any treatment becomes non-inferior to another
y suitable choice of the underlying assumptions. In general, if
uch trials are to be applied to clinical and regulatory decisions
egarding the marketing and use of new treatments, the
nderlying assumptions must be made explicit and their
nfluence on the resultant conclusions must be assessed rigor-
usly via sensitivity analyses. Thus, when these sensitivity
nalyses were applied to each of the key assumptionsnderlying the recently reported SPORTIF trials, they
aterially undermined the authors’ conclusion regarding the
on-inferiority of ximelagatran relative to warfarin in the
anagement of patients with AF.
eprint requests and correspondence: Dr. Sanjay Kaul, Division
f Cardiology, Cedars-Sinai Medical Center, 8700 Beverly Bou-
evard, Los Angeles, California 90048. E-mail: kaul@cshs.org.
EFERENCES
1. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning
WJ. Antithrombotic therapy in atrial fibrillation. The Seventh ACCP
Conference on Antithrombotic and Thrombolytic Therapy. Chest
2004;126:429S–56S.
2. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of
antithrombotic therapy in atrial fibrillation: analysis of pooled data
from five randomized controlled trials. Arch Intern Med 1994;154:
1449–57.
3. Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in
antiarrhythmic and antithrombotic medication use in atrial fibrillation.
Arch Intern Med 2004;164:55–60.
4. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor
ximelagatran compared with warfarin in patients with non-valvular
atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet
2003;362:1691–8.
5. Halperin JL. Ximelagatran: oral direct thrombin inhibition as antico-
agulant therapy in atrial fibrillation. J Am Coll Cardiol 2005;45:1–9.
6. SPORTIF Executive Steering Committee for the SPORTIF V
Investigators. Ximelagatran versus warfarin for stroke prevention in
patients with nonvalvular atrial fibrillation. A randomized trial. JAMA
2005;293:690–8.
7. Lawrence J, Hung J, Mahjoob K, reviewer. Statistical review and
evaluation, clinical studies, NDA 21-686 (2004). FDA web site.
Available at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-
4069B1_07_FDA Backgrounder-C-R-stat%20Review.pdf. Accessed
October 10, 2004.
8. Ellenberg SS, Temple R. Placebo-controlled trials and active-control
trials in the evaluation of new treatments. Part 1: ethical and scientific
issues. Ann Intern Med 2000 133:455–63.
9. Blackwelder W. Proving the null hypothesis in clinical trials. Control
Clin Trials 1982;3:345–53.
0. Siegel JP. Equivalence and non-inferiority trials. Am Heart J 2000;
139:S166–70.
1. Gould A. Another view of active-controlled trials. Control Clin Trials
1991;12:474–85.
2. Hasselblad V, Kong DF. Statistical methods for comparison to placebo
in active-control trials. Drug Inf J 2001;35:435–49.
3. Hung HMJ, Wang S-J, Tsong Y, et al. Some fundamental issues with
non-inferiority testing in active controlled trials. Stat Med 2003;22:
213–25.
4. D’Agostino RB Sr., Massaro JM, Sullivan LM. Non-inferiority trials:
design concepts and issues—the encounters of academic consultants in
statistics. Stat Med 2003;22:169–86.
5. Snapinn SM. Alternatives for discounting in the analysis of noninfe-
riority trials. J Biopharm Stat 2004;14:263–73.
6. International Conference on Harmonisation. Statistical principles for
clinical trials (ICH E 9) (1998); International Conference on Har-
monisation. Guidance on choice of control group and related design
and conduct issues in clinical trials (ICH E 10) (2000). Food and Drug
Administration, Department of Health and Human Services. Avail-
able at: http://www.fda.gov/cder/guidance/index.htm. Accessed Octo-
ber 17, 2005.
7. Conolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C.
Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am
Coll Cardiol 1991;18:349–55.
8. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the
prevention of stroke associated with nonrheumatic atrial fibrillation.
N Engl J Med 1992;327:1406–12.
12
2
2
2
2
2
1995JACC Vol. 46, No. 11, 2005 Kaul et al.
December 6, 2005:1986–95 Non-Inferiority Analysis of the SPORTIF Trials9. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in
Atrial Fibrillation study: final results. Circulation 1991;84:527–39.
0. The Boston Area Anticoagulation Trial for Atrial Fibrillation Inves-
tigators. The effect of low-dose warfarin on the risk of stroke in
patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:
1505–11.
1. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B.
Placebo-controlled, randomised trial of warfarin and aspirin for pre-
vention of thromboembolic complications in chronic atrial fibrillation.
Lancet 1989;175:179.2. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary
prevention in non-rheumatic atrial fibrillation after transient ischaemic
attack or minor stroke. Lancet 1993;342:1255–62.
3. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches
to randomized trials. J Royal Stat Soc Series A 1994;157:357–416.
4. Simon R. Bayesian design and analysis of active control clinical trials.
Biometrics 1999;55:484–7.
5. Diamond GA, Kaul S. Prior convictions: Bayesian approaches to the
analysis and interpretation of clinical megatrials. J Am Coll Cardiol
2004;43:1929–39.
